SA
CRDF icon

Scarborough Advisors’s Cardiff Oncology CRDF Stock Holding History

Scarborough Advisors’s Portfolio CRDF Stock Details CRDF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$16.2K Hold
10,502
– – ﹤0.01% 147
2026
Q1 		$17K Hold
10,502
– – ﹤0.01% 370
2025
Q4 		$29.5K Hold
10,502
– – 0.01% 174
2025
Q3 		$21.6K Buy
10,502
+3,000
+40% +$8.29K ﹤0.01% 197
2025
Q2 		$23.6K Buy
+7,502
New +$22.9K ﹤0.01% 178

Other funds holding CRDF

LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Scarborough Advisors's CRDF Position: Q2 2026 in Review

Scarborough Advisors held its Cardiff Oncology (CRDF) position steady in Q2 2026 at 10,502 shares worth $16.2K. The position accounts for ﹤0.01% of the portfolio, ranked #147.

Scarborough Advisors first reported a position in CRDF in Q2 2025 and has held it in 5 quarters since. The position peaked at $29.5K in Q4 2025. 105 funds tracked by Wall St. Rank hold CRDF as of Q2 2026.

  • Scarborough Advisors held 10,502 shares of Cardiff Oncology worth $16.2K as of Q2 2026.
  • Scarborough Advisors left its Cardiff Oncology share count unchanged in Q2 2026.
  • Cardiff Oncology made up ﹤0.01% of Scarborough Advisors's portfolio in Q2 2026, its #147 holding.
  • Scarborough Advisors first reported a position in Cardiff Oncology in Q2 2025 and has held it in 5 quarters since.
  • Scarborough Advisors's Cardiff Oncology position peaked at $29.5K in Q4 2025.
  • 105 funds tracked by Wall St. Rank held Cardiff Oncology as of Q2 2026.

Based on Scarborough Advisors's 13F filing for Q2 2026, filed 21 Jul 2026.